Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Abt-107. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 known ✓ | P36544 | 14/20 | 1.00 |
| ▸ | CHRNB2 | P17787 | 8/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.56 |
| ▸ | HTR3A | P46098 | 1/20 | 0.56 |
| ▸ | CHRNB4 | P30926 | 7/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 7/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.37 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Abt-107 SCHEMBL373047 | 1.00 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4HTR3ACHRNB4 | |
| Abt-107 SCHEMBL1542259 | 1.00 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4HTR3ACHRNB4 | |
| Abt-107 SCHEMBL29364159 | 1.00 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4HTR3ACHRNB4 | |
| Abt-107 SCHEMBL31393053 | 1.00 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4HTR3ACHRNB4 | |
| SCHEMBL3187225 | 0.93 | CHRNA7 (0.88) | CHRNA7CHRNB2CHRNA4HTR3ACHRNB4 | |
| Abt-107 SCHEMBL1542729 | 0.91 | CHRNA7 (0.83) | CHRNA7CHRNB2CHRNA4HTR3ACHRNB4 | |
| Abt-107 SCHEMBL1542457 | 0.91 | CHRNA7 (0.83) | CHRNA7CHRNB2CHRNA4HTR3ACHRNB4 | |
| Abt-107 SCHEMBL1542455 | 0.91 | CHRNA7 (0.83) | CHRNA7CHRNB2CHRNA4HTR3ACHRNB4 | |
| Abt-107 SCHEMBL1542724 | 0.91 | CHRNA7 (0.83) | CHRNA7CHRNB2CHRNA4HTR3ACHRNB4 | |
| Abt-107 SCHEMBL1542458 | 0.91 | CHRNA7 (0.83) | CHRNA7CHRNB2CHRNA4HTR3ACHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230102192-A1 | THERAPIES FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH ABNORMAL EXPRESSION OF A NEURAL-ASSOCIATED GENE | UNIV CALIFORNIA (US) | 2023-03-30 | — | — | US | claimed |
| US-20150352107-A1 | ALPHA7 NEURONAL NICOTINIC RECEPTOR LIGAND AND ANTIPSYCHOTIC COMPOSITIONS | ABBVIE INC. | 2015-12-10 | — | — | US | claimed |
| US-20130225560-A1 | Treatment of Cognitive Disorders with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Acetylcholinesterase Inhibitors | ENVIVO PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | claimed |
| EP-2598135-A1 | TREATMENT OF COGNITIVE DISORDERS WITH CERTAIN ALPHA-7 NICOTINIC ACID RECEPTOR AGONISTS IN COMBINATION WITH ACETYLCHOLINESTERASE INHIBITORS | Koenig, Gerhard (US) | 2013-06-05 | — | — | EP | claimed |
| WO-2012015749-A1 | TREATMENT OF COGNITIVE DISORDERS WITH CERTAIN ALPHA-7 NICOTINIC ACID RECEPTOR AGONISTS IN COMBINATION WITH ACETYLCHOLINESTERASE INHIBITORS | ENVIVO PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | claimed |
| EP-2308875-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives as .alpha.7 nAChR modulators | Abbott Laboratories (US) | 2011-04-13 | — | — | EP | claimed |
| US-7674794-B2 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES (US) | 2010-03-09 | — | — | US | claimed |
| US-20090221648-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-09-03 | — | — | US | claimed |
| WO-2009082698-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-07-02 | — | — | WO | claimed |
| EP-1863485-A2 | ALPHA7 NEURONAL NICOTINIC RECEPTOR LIGAND AND ANTIPSYCHOTIC COMPOSITIONS | ABBOTT LABORATORIES (US) | 2007-12-12 | — | — | EP | claimed |
| US-20070066592-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBVIE INC. | 2007-03-22 | — | — | US | claimed |
| US-20070060588-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES | 2007-03-15 | — | — | US | claimed |
| US-7160876-B2 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES (US) | 2007-01-09 | — | — | US | claimed |
| WO-2006101745-A2 | ALPHA7 NEURONAL NICOTINIC RECEPTOR LIGAND AND ANTIPSYCHOTIC COMPOSITIONS | ABBOTT LABORATORIES (US) | 2006-09-28 | — | — | WO | claimed |
| US-20060211686-A1 | Alpha7 Neuronal nicotinic receptor ligand and antipsychotic compositions | ABBOTT LABORATORIES | 2006-09-21 | — | — | US | claimed |
| US-20050245531-A1 | 5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-1H-indole; attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease, senile dementia, AIDS dementia, Pick's Disease, dementia associated with Down's syndrome; alpha 7 nAChR ligands modulators | ABBOTT LABORATORIES | 2005-11-03 | — | — | US | claimed |
| US-20050137204-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | claimed |
| US-20050137184-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBVIE INC. | 2005-06-23 | — | — | US | claimed |
| US-12215387-B2 | Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | NOVARTIS AG (CH) | 2025-02-04 | — | — | US | disclosed |
| US-20050137204-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060588-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | CHRNA1, CHRNA7, CHRNA2 | CHRNA7 2/4885CHRNB2 12/4885CHRNA4 10/4885 |
| US-20060211686-A1 | Alpha7 Neuronal nicotinic receptor ligand and antipsychotic compositions | CHRNA7, CHRNA5, CHRNA6 | CHRNA7 1/4885CHRNB2 10/4885CHRNA4 6/4885 |
| US-20230102192-A1 | THERAPIES FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH ABNORMAL EXPRESSION OF A NEURAL-ASSOCIATED GENE | CHRNA7, CHRNA3, CHRNA6 | CHRNA7 1/4885CHRNB2 9/4885CHRNA4 6/4885 |
| US-12215387-B2 | Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | CHRNA7, CHRNA4, CHRNA5 | CHRNA7 1/4885CHRNB2 9/4885CHRNA4 2/4885 |
| US-20130225560-A1 | Treatment of Cognitive Disorders with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Acetylcholinesterase Inhibitors | CHRNA7, CHRNA6, CHRNA2 | CHRNA7 1/4885CHRNB2 7/4885CHRNA4 6/4885 |
| US-20050137204-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | CHRNA1, CHRNA7, CHRNA2 | CHRNA7 2/4885CHRNB2 12/4885CHRNA4 10/4885 |
| US-20070066592-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | CHRNA1, CHRNA7, CHRNA2 | CHRNA7 2/4885CHRNB2 12/4885CHRNA4 9/4885 |
| US-20150352107-A1 | ALPHA7 NEURONAL NICOTINIC RECEPTOR LIGAND AND ANTIPSYCHOTIC COMPOSITIONS | CHRNA7, CHRNA5, CHRNA6 | CHRNA7 1/4885CHRNB2 10/4885CHRNA4 6/4885 |
| US-20050137184-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | CHRNA1, CHRNA7, CHRNA2 | CHRNA7 2/4885CHRNB2 12/4885CHRNA4 9/4885 |
| US-20090221648-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | CHRNA4, CHRNA5, CHRNA3 | CHRNA7 5/4885CHRNB2 12/4885CHRNA4 1/4885 |
| US-20050245531-A1 | 5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-1H-indole; attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease, senile dementia, AIDS dementia, Pick's Disease, dementia associated with Down's syndrome; alpha 7 nAChR ligands modulators | CHRNA7, CHRNA6, CHRNA10 | CHRNA7 1/4885CHRNB2 6/4885CHRNA4 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.